Cagrilintide
A once-weekly amylin analog developed primarily as a combination partner for semaglutide (CagriSema), adding amylin-pathway appetite suppression to GLP-1 activity.
A 37-amino-acid cyclic peptide analog of amylin with backbone modifications for prolonged half-life, engineered for weekly subcutaneous dosing in obesity combination regimens.
Mechanism of action
Dual agonism at amylin and calcitonin receptors. Amylin pathway activation suppresses food intake via hindbrain circuitry distinct from (and complementary to) GLP-1 appetite signaling, slows gastric emptying, and reduces glucagon secretion. Combination with semaglutide in CagriSema produced 22.7% weight loss at 68 weeks in REDEFINE 1 — numerically greater than semaglutide alone.
Primary uses
- Obesity — Phase 3 (as CagriSema combination)
- Type 2 diabetes — Phase 3
Typical dosing
In CagriSema trials: titrated over 16 weeks to 2.4 mg weekly. Not available as monotherapy.
Regulatory status
Investigational. Developed by Novo Nordisk. In Phase 3 as CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg, REDEFINE trial program) for obesity and T2DM.
References
- [clinical-trial] Enebo LB, et al. "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management." Lancet, 2021;397:1736-1748.
- [clinical-trial] ClinicalTrials.gov NCT05567796 (REDEFINE 1, Phase 3 obesity trial).
- [manufacturer] Novo Nordisk REDEFINE 1 topline results press release, March 2025.
Related peptides
This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.